TY - JOUR
T1 - Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013
AU - Mocroft, Amanda
AU - Lundgren, Jens
AU - Antinori, Andrea
AU - Monforte, Antonella d'Arminio
AU - Brännström, Johanna
AU - Bonnet, Fabrice
AU - Brockmeyer, Norbert
AU - Casabona, Jordi
AU - Castagna, Antonella
AU - Costagliola, Dominique
AU - de Wit, Stéphane
AU - Fätkenheuer, Gerd
AU - Furrer, Hansjakob
AU - Jadand, Corinne
AU - Johnson, Anne
AU - Lazanas, Mario
AU - Leport, Catherine
AU - Moreno, Santiago
AU - Mussini, Christina
AU - Obel, Niels
AU - Post, Frank
AU - Reiss, Peter
AU - Sabin, Caroline
AU - Skaletz-Rorowski, Adriane
AU - Suarez-Loano, Ignacio
AU - Torti, Carlo
AU - Warszawski, Josiane
AU - Wittkop, Linda
AU - Zangerle, Robert
AU - Chene, Genevieve
AU - Raben, Dorthe
AU - Kirk, Ole
AU - AUTHOR GROUP
AU - Touloumi, Giota
AU - Meyer, Laurence
AU - Dabis, François
AU - Krause, Murielle Mary
AU - Ghosn, Jade
AU - Wit, Ferdinand
AU - Prins, Maria
AU - Bucher, Heiner
AU - Gibb, Diana
AU - del Amo, Julia
AU - Thorne, Claire
AU - Stephan, Christoph
AU - Pérez-Hoyos, Santiago
AU - Hamouda, Osamah
AU - Bartmeyer, Barbara
AU - Chkhartishvili, Nikoloz
AU - Noguera-Julian, Antoni
AU - van der Valk, Marc
PY - 2015
Y1 - 2015
N2 - Late presentation (LP) for HIV care across Europe remains a significant issue. We provide a cross-European update from 34 countries on the prevalence and risk factors of LP for 2010-2013. People aged >= 16 presenting for HIV care (earliest of HIV-diagnosis, first clinic visit or cohort enrolment) after 1 January 2010 with available CD4 count within six months of presentation were included. LP was defined as presentation with a CD4 count <350/mm(3) or an AIDS defining event (at any CD4), in the six months following HIV diagnosis. Logistic regression investigated changes in LP over time. A total of 30,454 people were included. The median CD4 count at presentation was 368/mm(3) (interquartile range (IQR) 193-555/mm(3)), with no change over time (p = 0.70). In 2010, 4,775/10,766 (47.5%) were LP whereas in 2013, 1,642/3,375 (48.7%) were LP (p = 0.63). LP was most common in central Europe (4,791/9,625, 49.8%), followed by northern (5,704/11,692; 48.8%), southern (3,550/7,760; 45.8%) and eastern Europe (541/1,377; 38.3%; p <0.0001). There was a significant increase in LP in male and female people who inject drugs (PWID) (adjusted odds ratio (aOR)/year later 1.16; 95% confidence interval (CI): 1.02-1.32), and a significant decline in LP in northern Europe (aOR/year later 0.89; 95% CI: 0.85-0.94). Further improvements in effective HIV testing strategies, with a focus on vulnerable groups, are required across the European continent
AB - Late presentation (LP) for HIV care across Europe remains a significant issue. We provide a cross-European update from 34 countries on the prevalence and risk factors of LP for 2010-2013. People aged >= 16 presenting for HIV care (earliest of HIV-diagnosis, first clinic visit or cohort enrolment) after 1 January 2010 with available CD4 count within six months of presentation were included. LP was defined as presentation with a CD4 count <350/mm(3) or an AIDS defining event (at any CD4), in the six months following HIV diagnosis. Logistic regression investigated changes in LP over time. A total of 30,454 people were included. The median CD4 count at presentation was 368/mm(3) (interquartile range (IQR) 193-555/mm(3)), with no change over time (p = 0.70). In 2010, 4,775/10,766 (47.5%) were LP whereas in 2013, 1,642/3,375 (48.7%) were LP (p = 0.63). LP was most common in central Europe (4,791/9,625, 49.8%), followed by northern (5,704/11,692; 48.8%), southern (3,550/7,760; 45.8%) and eastern Europe (541/1,377; 38.3%; p <0.0001). There was a significant increase in LP in male and female people who inject drugs (PWID) (adjusted odds ratio (aOR)/year later 1.16; 95% confidence interval (CI): 1.02-1.32), and a significant decline in LP in northern Europe (aOR/year later 0.89; 95% CI: 0.85-0.94). Further improvements in effective HIV testing strategies, with a focus on vulnerable groups, are required across the European continent
U2 - https://doi.org/10.2807/1560-7917.ES.2015.20.47.30070
DO - https://doi.org/10.2807/1560-7917.ES.2015.20.47.30070
M3 - Article
C2 - 26624933
SN - 1025-496X
VL - 20
SP - 730070
EP - 730018
JO - Euro surveillance
JF - Euro surveillance
IS - 47
ER -